Related Experiment Video
Updated: Apr 18, 2026
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Incidence and Comparative Risk of Hematological Adverse Events Across Different Immune Checkpoint Inhibitors: A
Jaahnavi Vajje1, Nafisa Reyaz2, Iman Gillani3
1Internal Medicine, Dr.Pinnamaneni Siddhartha Institute of Medical Sciences and Research Foundation, Vijayawada, IND.
Cancer immunotherapy using immune checkpoint inhibitors (ICIs) shows varied risks for blood toxicities like anemia and neutropenia. Ipilimumab appears safest across these hematological adverse events (HAEs), suggesting potential differences in ICI safety profiles.
Area of Science:
- Oncology
- Pharmacology
- Clinical Research
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.
- Hematological adverse events (HAEs) associated with ICIs require further characterization.
- Understanding HAE profiles across different ICIs is crucial for patient safety.
Purpose of the Study:
- To systematically review and compare the incidence and risk of HAEs among various ICIs.
- To provide a comparative safety analysis of different immune checkpoint inhibitors regarding hematologic toxicities.
Main Methods:
- Systematic review and frequentist network meta-analysis of Phase II and III randomized controlled trials (RCTs).
- Literature search across major databases (PubMed, EMBASE, Cochrane, Web of Science) up to January 2026.
- Analysis focused on anemia, neutropenia, and thrombocytopenia, estimating odds ratios and rankings.
Main Results:
- Thirty-seven RCTs were included, analyzing diverse malignancies.
- Ipilimumab demonstrated the most favorable safety profile for anemia, neutropenia, and thrombocytopenia.
- Significant heterogeneity in HAE profiles was observed across different ICIs, with varying rankings for specific agents.
Conclusions:
- Substantial heterogeneity exists in the hematological safety profiles of ICIs.
- Ipilimumab consistently showed favorable rankings for anemia, neutropenia, and thrombocytopenia.
- Findings suggest potential differences in ICI hematologic safety, informing cautious treatment selection and monitoring strategies.
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...